TY - JOUR
T1 - Treatable subsets in cancer of unknown primary origin
AU - Sumi, H.
AU - Itoh, K.
AU - Onozawa, Y.
AU - Shigeoka, Y.
AU - Kodama, K.
AU - Ishizawa, K.
AU - Fujii, H.
AU - Minami, H.
AU - Igarashi, T.
AU - Sasaki, Y.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - The purpose of this study was to investigate the treatable subsets in cancer of unknown primary origin (CUP). Fifty patients (27 males and 23 females; median age, 53 years) with CUP diagnosed between April 1992 and June 1999 were analyzed retrospectively. Of the 50 patients, 39 received chemotherapy: platinum-based in 31, non-platinum-based in 4, and clinical trials of new agents in 4. Of the 39 patients, 13 (33.3%; 95% confidence interval: 19:1-50.2%) showed objective responses, with 4 complete responders. Patients with poorly differentiated carcinomas in whom β-subunit of human chorionic gonadotropin (β-HCG) was elevated more than 10 mIU/ml and female patients with peritoneal adenocarcinomatosis achieved high response rates (83.3% and 80%, respectively) with platinum-based chemotherapy, as compared with only a 15.3% response rate in the remaining patients. Platinum-based chemotherapy provided promising results in patients with poorly differentiated carcinomas and in female patients with peritoneal adenocarcinomatosis. Significantly elevated serum levels of β-HCG in patients with poorly differentiated carcinoma might predict a better response to platinum-based chemotherapy. However, the investigation of novel chemotherapeutic approaches is warranted for other groups of patients with CUP.
AB - The purpose of this study was to investigate the treatable subsets in cancer of unknown primary origin (CUP). Fifty patients (27 males and 23 females; median age, 53 years) with CUP diagnosed between April 1992 and June 1999 were analyzed retrospectively. Of the 50 patients, 39 received chemotherapy: platinum-based in 31, non-platinum-based in 4, and clinical trials of new agents in 4. Of the 39 patients, 13 (33.3%; 95% confidence interval: 19:1-50.2%) showed objective responses, with 4 complete responders. Patients with poorly differentiated carcinomas in whom β-subunit of human chorionic gonadotropin (β-HCG) was elevated more than 10 mIU/ml and female patients with peritoneal adenocarcinomatosis achieved high response rates (83.3% and 80%, respectively) with platinum-based chemotherapy, as compared with only a 15.3% response rate in the remaining patients. Platinum-based chemotherapy provided promising results in patients with poorly differentiated carcinomas and in female patients with peritoneal adenocarcinomatosis. Significantly elevated serum levels of β-HCG in patients with poorly differentiated carcinoma might predict a better response to platinum-based chemotherapy. However, the investigation of novel chemotherapeutic approaches is warranted for other groups of patients with CUP.
KW - Cancer of unknown primary
KW - Chemosensitive subroups
KW - Chemotherapy
KW - β-HCG
UR - http://www.scopus.com/inward/record.url?scp=0034942229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034942229&partnerID=8YFLogxK
U2 - 10.1111/j.1349-7006.2001.tb01151.x
DO - 10.1111/j.1349-7006.2001.tb01151.x
M3 - Article
C2 - 11429061
AN - SCOPUS:0034942229
VL - 92
SP - 704
EP - 709
JO - Cancer Science
JF - Cancer Science
SN - 1347-9032
IS - 6
ER -